Ruxolitinib deuterated - Concert Pharmaceuticals

Drug Profile

Ruxolitinib deuterated - Concert Pharmaceuticals

Alternative Names: CTP-543; Deuterated ruxolitinib; Deuterium ruxolitinib analogue - Concert Pharmaceuticals

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alopecia areata

Most Recent Events

  • 12 Jan 2018 The Patent Trial and Appeal Board denies Post Grant Review petition of Concert Pharmaceuticals filed to challenge US patent 9 662 335 covering deuterated ruxolitinib analogues in USA
  • 12 Jan 2018 Ruxolitinib deuterated - Concert Pharmaceuticals receives Fast Track designation for Alopecia areata [PO,Tablet,bid] in USA
  • 19 Oct 2017 The Patent Trial and Appeal Board denies Incyte’s petition to institute inter partes review (IPR) of US Patent No. 9 249 149 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top